{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:15:37Z","timestamp":1793312137261,"version":"4.5.0"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to immunotherapy due to its highly immunosuppressive tumor microenvironment (TME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review aims to elucidate the key mechanisms of TME-mediated immune evasion in PDAC and explore therapeutic strategies to overcome these barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive analysis of recent studies was conducted, focusing on the cellular, stromal, and metabolic components of the PDAC TME, alongside emerging technologies for TME reprogramming.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dense extracellular matrix, CAF-driven fibrosis, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), Tregs, and metabolic competition collectively impair immune cell infiltration and activation. Novel interventions\u2014including ECM remodeling, CAF modulation, metabolic reprogramming, and myeloid cell targeting\u2014show promise in restoring immune responsiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TME reprogramming represents a critical strategy to enhance immunotherapy efficacy in PDAC, offering new opportunities for overcoming immune exclusion and resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1717062","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T07:10:02Z","timestamp":1763449802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Reprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Xianfeng","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiesuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000529374","article-title":"Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide","volume":"54","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13561-024-00517-3","article-title":"The effects of Medicaid expansion on the racial\/ethnic composition within nursing home residents","volume":"14","author":"Loaiza","year":"2024","journal-title":"Health Econ Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-023-07994-1","article-title":"Equine tapeworm (Anoplocephala spp.) infection: evaluation of saliva- and serum-based antibody detection methods and risk factor analysis in Slovak horse populations","volume":"122","author":"Burcakova","year":"2023","journal-title":"Parasitol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"109500","DOI":"10.3748\/wjg.v31.i26.109500","article-title":"Serum exosomal hsa-let-7f-5p: A potential diagnostic biomarker for metastatic pancreatic cancer detection","volume":"31","author":"Ren","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"109373","DOI":"10.4329\/wjr.v17.i8.109373","article-title":"Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer","volume":"17","author":"Ren","year":"2025","journal-title":"World J Radiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cancergen.2025.06.006","article-title":"SATB2 plays a critical role in pancreatic cancer cell proliferation, migration and T cell cytotoxicity","author":"Jiang","year":"2025","journal-title":"Cancer Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582305","article-title":"Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets","volume":"16","author":"Pan","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40169-019-0226-9","article-title":"Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma","volume":"8","author":"Daniel","year":"2019","journal-title":"Clin Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221924","article-title":"Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for cancer immunotherapy","volume":"13","author":"Rahman","year":"2024","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options","volume":"9","author":"Kabacaoglu","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"217699","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - Exploring the \"Space","volume":"622","author":"Brautigam","year":"2025","journal-title":"Cancer Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2024.029","article-title":"Tumor stroma as a therapeutic target for pancreatic ductal adenocarcinoma","volume":"32","author":"Lee","year":"2024","journal-title":"Biomol Ther (Seoul)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/path.5224","article-title":"Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma","volume":"248","author":"Neuzillet","year":"2019","journal-title":"J Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in alphaSMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Ohlund","year":"2017","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2023.02.007","article-title":"Tumor microenvironment interactions with cancer stem cells in pancreatic ductal adenocarcinoma","volume":"159","author":"Palma","year":"2023","journal-title":"Adv Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2023.02.007","article-title":"Lauth M. A quick guide to CAF subtypes in pancreatic cancer","volume":"15","author":"Brichkina","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515390","article-title":"Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity","volume":"16","author":"Mentucci","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573522","article-title":"Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma","volume":"16","author":"Ramesh","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.21037\/atm-23-1882","article-title":"Dendritic cell vaccination combined with irreversible electroporation for treating pancreatic cancer-a narrative review","volume":"12","author":"Zhang","year":"2024","journal-title":"Ann Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.607209","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202264","article-title":"Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition","volume":"13","author":"Xiong","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8164","article-title":"Macrophage transcriptome modification induced by hypoxia and lactate","volume":"18","author":"Zhao","year":"2019","journal-title":"Exp Ther Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8602","article-title":"Lactate supports a metabolic-epigenetic link in macrophage polarization","volume":"7","author":"Noe","year":"2021","journal-title":"Sci Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-directed tumor microenvironment modulation in cancer immunotherapy","volume":"22","author":"Bule","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091551","article-title":"An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma","volume":"9","author":"Tang","year":"2014","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1406250","article-title":"Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma","volume":"15","author":"Smith","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/intimm\/dxae042","article-title":"Diverse roles of dendritic cell and regulatory T cell crosstalk in controlling health and disease","volume":"37","author":"Yamazaki","year":"2024","journal-title":"Int Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457189","article-title":"Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations","volume":"15","author":"Ge","year":"2024","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720113115","article-title":"Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth","volume":"115","author":"Pacella","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12944-022-01705-y","article-title":"Lipid metabolic features of T cells in the Tumor Microenvironment","volume":"21","author":"Lou","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41577-025-01171-4","article-title":"Brief blockade of type I IFN increases CD8(+) T cell memory","volume":"25","author":"Bird","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"13731","DOI":"10.1038\/ncomms13731","article-title":"Photonic Weyl point in a two-dimensional resonator lattice with a synthetic frequency dimension","volume":"7","author":"Lin","year":"2016","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nm892","article-title":"Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea","volume":"9","author":"Kirvan","year":"2003","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13046-023-02845-4","article-title":"Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity","volume":"42","author":"Zheng","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310668","article-title":"Unlocking the potential of arginine deprivation therapy: recent breakthroughs and promising future for cancer treatment","volume":"24","author":"Chu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070643","article-title":"The influence of myeloid-derived suppressor cell expansion in neuroinflammation and neurodegenerative diseases","volume":"13","author":"Tamberi","year":"2024","journal-title":"Cells"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i27.3297","article-title":"Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy","volume":"28","author":"Smith","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.044","article-title":"Fibroblasts in pancreatic ductal adenocarcinoma: biological mechanisms and therapeutic targets","volume":"156","author":"Whittle","year":"2019","journal-title":"Gastroenterology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"122631","DOI":"10.1016\/j.biomaterials.2024.122631","article-title":"A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism","volume":"310","author":"Li","year":"2024","journal-title":"Biomaterials"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143466","article-title":"Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy","volume":"13","author":"Belhabib","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217898","article-title":"CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation","volume":"217898","author":"Yao","year":"2025","journal-title":"Cancer Lett"},{"key":"B65","doi-asserted-by":"publisher","first-page":"105317","DOI":"10.1016\/j.isci.2022.105317","article-title":"Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer","volume":"25","author":"Sarhan","year":"2022","journal-title":"iScience"},{"key":"B66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00160","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2019","journal-title":"Front Mol Biosci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202100285","article-title":"The solid tumor microenvironment-Breaking the barrier for T cells: How the solid tumor microenvironment influences T cells: How the solid tumor microenvironment influences T cells","volume":"44","author":"Simsek","year":"2022","journal-title":"Bioessays"},{"key":"B69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13046-019-1086-2","article-title":"3D models in the new era of immune oncology: focus on T cells, CAF and ECM","volume":"38","author":"Di Modugno","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155486","article-title":"Crosstalk between tumor and stromal cells in pancreatic ductal adenocarcinoma","volume":"21","author":"Sperb","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133308","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961637","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174442","article-title":"The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options","volume":"13","author":"Ferrara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","article-title":"Targeting pancreatic cancer metabolic dependencies through glutamine antagonism","volume":"5","author":"Encarnacion-Rosado","year":"2024","journal-title":"Nat Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549276","article-title":"Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12943-022-01645-2","article-title":"The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies","volume":"21","author":"Bai","year":"2022","journal-title":"Mol Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1520032112","article-title":"HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B78","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41419-024-07122-6","article-title":"Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment","volume":"15","author":"Zheng","year":"2024","journal-title":"Cell Death Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"101150","DOI":"10.1016\/j.jpha.2024.101150","article-title":"Targeting tumor metabolism to augment CD8(+) T cell anti-tumor immunity","volume":"15","author":"Liu","year":"2025","journal-title":"J Pharm Anal"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2025.04.007","article-title":"Tumor-stromal metabolic crosstalk in pancreatic cancer","author":"Thakur","year":"2025","journal-title":"Trends Cell Biol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122995","article-title":"Interactions between cancer-associated fibroblasts and T cells in the pancreatic tumor microenvironment and the role of chemokines","volume":"13","author":"Gorchs","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1431598","article-title":"Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells","volume":"14","author":"Thepmalee","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-021-01376-w","article-title":"The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells","volume":"20","author":"Hosseini","year":"2021","journal-title":"Mol Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"106880","DOI":"10.1016\/j.phrs.2023.106880","article-title":"Emerging role of exosome-shuttled noncoding RNAs in gastrointestinal cancers: From intercellular crosstalk to clinical utility","volume":"195","author":"Xia","year":"2023","journal-title":"Pharmacol Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12964-021-00789-w","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun Signal"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00475-9","article-title":"Scaling the immune incline in PDAC","volume":"18","author":"Rojas","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/biom11060901","article-title":"Immune cell modulation of the extracellular matrix contributes to the pathogenesis of pancreatic cancer","volume":"11","author":"Ahmad","year":"2021","journal-title":"Biomolecules"},{"key":"B91","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-021-00271-4","article-title":"Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response","volume":"7","author":"Wang","year":"2021","journal-title":"Cell Discov"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.66","article-title":"T-cell programming in pancreatic adenocarcinoma: a review","volume":"24","author":"Seo","year":"2017","journal-title":"Cancer Gene Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01044","article-title":"Pancreatic ductal adenocarcinoma: A strong imbalance of good and bad immunological cops in the tumor microenvironment","volume":"9","author":"Foucher","year":"2018","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038650","article-title":"Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression","volume":"13","author":"Dong","year":"2022","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","article-title":"Emerging mechanisms and promising approaches in pancreatic cancer metabolism","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12944-023-01807-1","article-title":"Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy","volume":"22","author":"Qiao","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1142838","article-title":"The immunomodulatory role of IDO1-Kynurenine-NAD(+) pathway in switching cold tumor microenvironment in PDAC","volume":"13","author":"Anu","year":"2023","journal-title":"Front Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i12.3471","article-title":"Glucose metabolic phenotype of pancreatic cancer","volume":"22","author":"Chan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: From immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122860","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges","volume":"13","author":"Poh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225475","article-title":"Galectins are central mediators of immune escape in pancreatic ductal adenocarcinoma","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184639","article-title":"Association between AHR expression and immune dysregulation in pancreatic ductal adenocarcinoma: insights from comprehensive immune profiling of peripheral blood mononuclear cells","volume":"15","author":"Bartkeviciene","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112619","article-title":"The next frontier in pancreatic cancer: targeting the tumor immune milieu and molecular pathways","volume":"14","author":"Yin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw2937","article-title":"Targeting tumor-associated CCR2(+) macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation","volume":"11","author":"Xu","year":"2025","journal-title":"Sci Adv"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35945","article-title":"Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study)","volume":"131","author":"Ramaswamy","year":"2025","journal-title":"Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S447350","article-title":"The application of nanoparticles targeting cancer-associated fibroblasts","volume":"19","author":"Huang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01908-7","article-title":"Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities","author":"Yang","year":"2025","journal-title":"Drug Delivery Transl Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","article-title":"Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery","volume":"24","author":"Sabit","year":"2025","journal-title":"Mol Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00950-z","article-title":"Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy","volume":"16","author":"Wang","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"B129","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01084-2","article-title":"Will the Biden administration 'follow the science' on regulatory reform","volume":"39","author":"Cohrssen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41587-021-01017-z","article-title":"Publisher Correction: Questions swirl around failures of disease-modifying Huntington's drugs","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010101","article-title":"Chimeric antigen receptor T cell therapy for pancreatic cancer: A review of current evidence","volume":"13","author":"Czaplicka","year":"2024","journal-title":"Cells"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1876-x","article-title":"The single-cell pathology landscape of breast cancer","volume":"578","author":"Jackson","year":"2020","journal-title":"Nature"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00954-4","article-title":"A generalized linear mixed model association tool for biobank-scale data","volume":"53","author":"Jiang","year":"2021","journal-title":"Nat Genet"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0462-y","article-title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","volume":"25","author":"Kather","year":"2019","journal-title":"Nat Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized study platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2543614","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"Oncoimmunology"},{"key":"B141","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","article-title":"First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial","volume":"9","author":"Sha","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B142","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ccell.2020.09.004","article-title":"Immunometabolic interplay in the tumor microenvironment","volume":"39","author":"Kaymak","year":"2021","journal-title":"Cancer Cell"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i4.1256","article-title":"Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma","volume":"16","author":"Ren","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B144","article-title":"Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology","volume":"11","author":"Selby","year":"2016","journal-title":"PLoS One"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1380453","article-title":"Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis","volume":"14","author":"O'Reilly","year":"2024","journal-title":"Front Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1151595","article-title":"Timing of CSF-1\/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy","volume":"5","author":"Holmgaard","year":"2016","journal-title":"Oncoimmunology"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26968","article-title":"CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells","volume":"2","author":"Strachan","year":"2013","journal-title":"Oncoimmunology"},{"key":"B148","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/OA-24-00050","article-title":"Challenges and opportunities in targeting the complex pancreatic tumor microenvironment","volume":"1","author":"Finan","year":"2024","journal-title":"JCO Oncol Adv"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187024","article-title":"Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma","volume":"135","author":"Sun","year":"2025","journal-title":"J Clin Invest"},{"key":"B151","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70070","article-title":"The microbiome in cancer","volume":"4","author":"Lin","year":"2025","journal-title":"Imeta"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022040","article-title":"CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice","volume":"143","author":"Adams","year":"2024","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1277076","article-title":"Metastasis and cancer associated fibroblasts: taking it up a NOTCH","volume":"11","author":"Ghosh","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13578-023-01073-9","article-title":"Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms","volume":"13","author":"Wang","year":"2023","journal-title":"Cell Biosci"},{"key":"B162","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br J Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"217613","DOI":"10.1016\/j.canlet.2025.217613","article-title":"Unraveling UPR-mediated intercellular crosstalk: Implications for immunotherapy resistance mechanisms","volume":"617","author":"Lu","year":"2025","journal-title":"Cancer Lett"},{"key":"B164","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12967-025-06371-z","article-title":"From virtual to reality: innovative practices of digital twins in tumor therapy","volume":"23","author":"Shen","year":"2025","journal-title":"J Transl Med"},{"key":"B165","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","article-title":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-beta signal","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol Ther"},{"key":"B166","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.xcrm.2021.100227","article-title":"Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1717062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T07:10:04Z","timestamp":1763449804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1717062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":166,"alternative-id":["10.3389\/fimmu.2025.1717062"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1717062","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1717062"}}